Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Drop in Short Interest

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) saw a significant drop in short interest in September. As of September 30th, there was short interest totaling 33,851 shares, a drop of 97.4% from the September 15th total of 1,297,436 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 130,379 shares, the short-interest ratio is currently 0.3 days.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.6%

SGIOY traded down $0.05 during trading on Friday, hitting $8.70. The company had a trading volume of 131,152 shares, compared to its average volume of 188,565. Shionogi & Co., Ltd. Unsponsored ADR has a 1-year low of $7.65 and a 1-year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00. The company has a market cap of $14.81 billion, a PE ratio of 8.70, a P/E/G ratio of 3.14 and a beta of 0.08. The business has a 50-day moving average of $9.07 and a 200-day moving average of $9.33.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.18. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. As a group, analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SGIOY shares. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.